GCG and type 2 diabetes mellitus: Due to its incretin effect (insulin secretion after a meal, in a glucose-dependent manner) GLP-1 is one of the most promising therapeutic molecules for T2DM therapy, avoiding the well-known hypoglycemic effects of current drugs.9,10 Nevertheless, GLP-1 has a very short half-life, being cleaved by the DPP4 enzyme in less than 2 minutes.11 This system was assembled through the droplet microfluidics technique8 and it is based on the use of polymeric poly(lactic-co-glycolic acid) (PLGA) nanoparticles.